Adrenergic Drug Market - Regional Analysis
North American Market Insights
The North America industry is likely to account for largest revenue share of 35% by 2035. The major factor to encourage this growth is the rising prevalence of chronic disease. Nearly half of all Americans, or about 132 million people, are believed to suffer from a minimum of one chronic ailment, such as arthritis, heart disease, or hypertension. That number is projected to rise to over 169 million by 2030, which is about 14 million more than it was even ten years ago. Moreover, this region is considered to be the most active for various launches of medication since they have the highest spending on pharmaceuticals. Also, there has been an upsurge in patient population in this region and hence this region might also be held responsible for the spending on launch medication. Hence, the demand for market in this region is expanding.
APAC Market Insights
The adrenergic drug market in Asia Pacific is also expected to experience the significant growth over the forecast period. This growth is set to be influenced by the growth in the prevalence of COPD. Despite being a condition that can potentially be prevented and treated, chronic obstructive pulmonary disease (COPD) is associated with high morbidity and mortality, resulting in a significant social and economic burden. The Epidemiology and Impact of COPD (EPIC) Asia population-based survey results indicate a high incidence of COPD in the participating Asia-Pacific territories and a significant socioeconomic burden of the disease in this region. As a result, the importance for adrenergic drug is rising in order to cure and this disease. Additionally, there has been surge in awareness regarding cardiovascular disease in Asia Pacific and the medication available for this. Hence, this is also projected to encourage the adrenergic drug market growth in this region.
